Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Antibody-dependent IFN-γ-independent sterilizing immunity, induced by a subunit malaria vaccine.

Chawla B, Mahajan B, Oakley M, Majam VF, Belmonte A, Sedegah M, Shimp RL Jr, Kaslow DC, Kumar S.

Infect Immun. 2019 Jul 15. pii: IAI.00236-19. doi: 10.1128/IAI.00236-19. [Epub ahead of print]

PMID:
31308085
2.

Antigenicity and immune correlate assessment of seven Plasmodium falciparum antigens in a longitudinal infant cohort from northern Ghana.

Kusi KA, Aguiar J, Kumordjie S, Aggor F, Bolton J, Renner A, Kyei-Baafour E, Puplampu N, Belmonte M, Dodoo D, Gyan BA, Ofori MF, Oduro AR, Atuguba F, Koram KA, Adams N, Letizia A, Villasante E, Sedegah M.

Sci Rep. 2019 Jun 13;9(1):8621. doi: 10.1038/s41598-019-45092-4.

3.

T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development.

Nlinwe ON, Kusi KA, Adu B, Sedegah M.

Vaccine. 2018 Apr 19;36(17):2237-2242. doi: 10.1016/j.vaccine.2018.03.023. Epub 2018 Mar 21. Review.

PMID:
29573877
4.

Profiling the Targets of Protective CD8+ T Cell Responses to Infection.

Bruder JT, Chen P, Ekberg G, Smith EC, Lazarski CA, Myers BA, Bolton J, Sedegah M, Villasante E, Richie TL, King CR, Aguiar JC, Doolan DL, Brough DE.

Mol Ther Methods Clin Dev. 2017 Aug 18;7:20-31. doi: 10.1016/j.omtm.2017.08.003. eCollection 2017 Dec 15.

5.

New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.

Limbach K, Stefaniak M, Chen P, Patterson NB, Liao G, Weng S, Krepkiy S, Ekberg G, Torano H, Ettyreddy D, Gowda K, Sonawane S, Belmonte A, Abot E, Sedegah M, Hollingdale MR, Moormann A, Vulule J, Villasante E, Richie TL, Brough DE, Bruder JT.

Malar J. 2017 Jul 3;16(1):263. doi: 10.1186/s12936-017-1911-z.

6.

Cellular immune response to DNA and vaccinia prime-boost immunization kills Plasmodium yoelii-infected hepatocytes in vitro.

Sacci JB Jr, Hollingdale MR, Sedegah M.

Pathog Dis. 2017 Jun 1;75(4). doi: 10.1093/femspd/ftx051.

PMID:
28475711
7.

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine.

Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, Chakravarty S, Stafford A, Ruck RC, Eappen AG, Li T, Billingsley PF, Manoj A, Silva JC, Moser K, Nielsen R, Tosh D, Cicatelli S, Ganeshan H, Case J, Padilla D, Davidson S, Garver L, Saverino E, Murshedkar T, Gunasekera A, Twomey PS, Reyes S, Moon JE, James ER, Kc N, Li M, Abot E, Belmonte A, Hauns K, Belmonte M, Huang J, Vasquez C, Remich S, Carrington M, Abebe Y, Tillman A, Hickey B, Regules J, Villasante E, Sim BKL, Hoffman SL.

JCI Insight. 2017 Jan 12;2(1):e89154. doi: 10.1172/jci.insight.89154.

8.

Correction: Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.

Sedegah M, Peters B, Hollingdale MR, Ganeshan HD, Huang J, Farooq F, Belmonte MN, Belmonte AD, Limbach KJ, Diggs C, Soisson L, Chuang I, Villasante ED.

PLoS One. 2016 Dec 20;11(12):e0168952. doi: 10.1371/journal.pone.0168952. eCollection 2016.

9.

Seroprevalence of Antibodies against Plasmodium falciparum Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission.

Kusi KA, Bosomprah S, Kyei-Baafour E, Dickson EK, Tornyigah B, Angov E, Dutta S, Dodoo D, Sedegah M, Koram KA.

PLoS One. 2016 Nov 22;11(11):e0167175. doi: 10.1371/journal.pone.0167175. eCollection 2016.

10.

Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.

Sedegah M, Peters B, Hollingdale MR, Ganeshan HD, Huang J, Farooq F, Belmonte MN, Belmonte AD, Limbach KJ, Diggs C, Soisson L, Chuang I, Villasante ED.

PLoS One. 2016 Oct 3;11(10):e0163026. doi: 10.1371/journal.pone.0163026. eCollection 2016. Erratum in: PLoS One. 2016 Dec 20;11(12 ):e0168952.

11.

Development of replication-deficient adenovirus malaria vaccines.

Hollingdale MR, Sedegah M, Limbach K.

Expert Rev Vaccines. 2017 Mar;16(3):261-271. doi: 10.1080/14760584.2016.1228454. Epub 2016 Sep 8. Review.

PMID:
27606709
12.

Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity.

Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, Luke TC, Charoenvit Y, Goh LM, Berzins MP, Bebris L, Sacci JB Jr, De La Vega P, Wang R, Ganeshan H, Abot EN, Carucci DJ, Doolan DL, Brice GT, Kumar A, Aguiar J, Nutman TB, Leitman SF, Hoffman SL, Epstein JE, Richie TL.

Malar J. 2016 Jul 22;15(1):377. doi: 10.1186/s12936-016-1435-y.

13.

Decrease in circulating CD25(hi)Foxp3(+) regulatory T cells following vaccination with the candidate malaria vaccine RTS,S.

Parsons E, Epstein J, Sedegah M, Villasante E, Stewart A.

Vaccine. 2016 Aug 31;34(38):4618-4625. doi: 10.1016/j.vaccine.2016.07.008. Epub 2016 Jul 18.

PMID:
27443592
14.

Development of whole sporozoite malaria vaccines.

Hollingdale MR, Sedegah M.

Expert Rev Vaccines. 2017 Jan;16(1):45-54. Epub 2016 Jul 18. Review.

PMID:
27327875
15.

Plasma concentrations of transforming growth factor beta 1 in non-progressive HIV-1 infection correlates with markers of disease progression.

Maina EK, Abana CZ, Bukusi EA, Sedegah M, Lartey M, Ampofo WK.

Cytokine. 2016 May;81:109-16. doi: 10.1016/j.cyto.2016.02.009. Epub 2016 Mar 14.

PMID:
26986868
16.

Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria.

Ganeshan H, Kusi KA, Anum D, Hollingdale MR, Peters B, Kim Y, Tetteh JK, Ofori MF, Gyan BA, Koram KA, Huang J, Belmonte M, Banania JG, Dodoo D, Villasante E, Sedegah M.

Malar J. 2016 Feb 1;15:55. doi: 10.1186/s12936-016-1098-8.

17.

Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein.

Parra M, Liu X, Derrick SC, Yang A, Molina-Cruz A, Barillas-Mury C, Zheng H, Thao Pham P, Sedegah M, Belmonte A, Litilit DD, Waldmann TA, Kumar S, Morris SL, Perera LP.

PLoS One. 2015 Oct 27;10(10):e0141141. doi: 10.1371/journal.pone.0141141. eCollection 2015.

18.

CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.

Maina EK, Bonney EY, Bukusi EA, Sedegah M, Lartey M, Ampofo WK.

Immunol Lett. 2015 Dec;168(2):279-84. doi: 10.1016/j.imlet.2015.10.005. Epub 2015 Oct 22. Review.

PMID:
26475399
19.

The Ex Vivo IFN-γ Enzyme-Linked Immunospot (ELISpot) Assay.

Sedegah M.

Methods Mol Biol. 2015;1325:197-205. doi: 10.1007/978-1-4939-2815-6_16.

PMID:
26450390
20.

Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development.

Aguiar JC, Bolton J, Wanga J, Sacci JB, Iriko H, Mazeika JK, Han ET, Limbach K, Patterson NB, Sedegah M, Cruz AM, Tsuboi T, Hoffman SL, Carucci D, Hollingdale MR, Villasante ED, Richie TL.

PLoS One. 2015 Aug 20;10(8):e0136109. doi: 10.1371/journal.pone.0136109. eCollection 2015.

21.

Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming.

Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Huang J, Abot E, Limbach K, Chuang I, Tamminga C, Epstein JE, Villasante E.

Hum Vaccin Immunother. 2015;11(11):2705-15. doi: 10.1080/21645515.2015.1019186. Epub 2015 Aug 20.

22.

Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.

Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J, Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.

PLoS One. 2015 Jul 6;10(7):e0131571. doi: 10.1371/journal.pone.0131571. eCollection 2015.

23.

Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.

Anum D, Kusi KA, Ganeshan H, Hollingdale MR, Ofori MF, Koram KA, Gyan BA, Adu-Amankwah S, Badji E, Huang J, Belmonte M, Banania GJ, Kwofie TB, Villasante E, Dodoo D, Sedegah M.

Malar J. 2015 Jan 21;14:20. doi: 10.1186/s12936-014-0539-5.

24.

Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.

Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, Peters B, Sette A, Huang J, McGrath S, Abot E, Limbach K, Shi M, Soisson L, Diggs C, Chuang I, Tamminga C, Epstein JE, Villasante E, Richie TL.

PLoS One. 2014 Sep 11;9(9):e106241. doi: 10.1371/journal.pone.0106241. eCollection 2014.

25.

Anti-sporozoite antibodies as alternative markers for malaria transmission intensity estimation.

Kusi KA, Bosomprah S, Dodoo D, Kyei-Baafour E, Dickson EK, Mensah D, Angov E, Dutta S, Sedegah M, Koram KA.

Malar J. 2014 Mar 17;13:103. doi: 10.1186/1475-2875-13-103.

26.

A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates.

Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, Coelho-dos-Reis JG, Li X, Wu D, Bruder JT, Sedegah M, Patterson N, Richie TL, Wong CH, Ho DD, Vasan S, Tsuji M.

PLoS One. 2013 Oct 25;8(10):e78407. doi: 10.1371/journal.pone.0078407. eCollection 2013.

27.

Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1.

Schwenk R, Banania G, Epstein J, Kim Y, Peters B, Belmonte M, Ganeshan H, Huang J, Reyes S, Stryhn A, Ockenhouse CF, Buus S, Richie TL, Sedegah M.

Malar J. 2013 Oct 29;12:376. doi: 10.1186/1475-2875-12-376.

28.

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.

Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL; VRC 312 Study Team.

Science. 2013 Sep 20;341(6152):1359-65. doi: 10.1126/science.1241800. Epub 2013 Aug 8.

29.

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.

Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, Vasquez C, Alcorta Y, Chuang I, Spring M, Kavanaugh M, Ganeshan H, Huang J, Belmonte M, Abot E, Belmonte A, Banania J, Farooq F, Murphy J, Komisar J, Richie NO, Bennett J, Limbach K, Patterson NB, Bruder JT, Shi M, Miller E, Dutta S, Diggs C, Soisson LA, Hollingdale MR, Epstein JE, Richie TL.

Hum Vaccin Immunother. 2013 Oct;9(10):2165-77. doi: 10.4161/hv.24941. Epub 2013 Jun 4.

30.

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP).

Sedegah M, Kim Y, Ganeshan H, Huang J, Belmonte M, Abot E, Banania JG, Farooq F, McGrath S, Peters B, Sette A, Soisson L, Diggs C, Doolan DL, Tamminga C, Villasante E, Hollingdale MR, Richie TL.

Malar J. 2013 Jun 5;12:185. doi: 10.1186/1475-2875-12-185.

31.

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14.

32.

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB Jr, Sedegah M, Nosek RA Jr, De La Vega P, Berzins MP, Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.

33.

Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system.

Freimanis G, Sedegah M, Owusu-Ofori S, Kumar S, Allain JP.

Transfusion. 2013 Jul;53(7):1429-41. doi: 10.1111/j.1537-2995.2012.03943.x. Epub 2012 Nov 1.

PMID:
23113534
34.

Polymerase chain reaction-based tests for pan-species and species-specific detection of human Plasmodium parasites.

Mahajan B, Zheng H, Pham PT, Sedegah MY, Majam VF, Akolkar N, Rios M, Ankrah I, Madjitey P, Amoah G, Addison E, Quakyi IA, Kumar S.

Transfusion. 2012 Sep;52(9):1949-56. doi: 10.1111/j.1537-2995.2011.03541.x. Epub 2012 Feb 10.

PMID:
22320188
35.

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.

Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868. Epub 2011 Oct 7.

36.

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.

Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL.

PLoS One. 2011;6(10):e24586. doi: 10.1371/journal.pone.0024586. Epub 2011 Oct 7.

37.

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity.

Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL.

Science. 2011 Oct 28;334(6055):475-80. doi: 10.1126/science.1211548. Epub 2011 Sep 8.

38.

Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, Ocran J, Adu-Amankwah S, Geneshan H, Abot E, Legano J, Banania G, Sayo R, Brambilla D, Kumar S, Doolan DL, Rogers WO, Epstein J, Richie TL, Sedegah M.

Malar J. 2011 Jun 20;10:168. doi: 10.1186/1475-2875-10-168.

39.

Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates.

Limbach K, Aguiar J, Gowda K, Patterson N, Abot E, Sedegah M, Sacci J, Richie T.

Malar J. 2011 Mar 16;10:65. doi: 10.1186/1475-2875-10-65.

40.

Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Sedegah M, Kim Y, Peters B, McGrath S, Ganeshan H, Lejano J, Abot E, Banania G, Belmonte M, Sayo R, Farooq F, Doolan DL, Regis D, Tamminga C, Chuang I, Bruder JT, King CR, Ockenhouse CF, Faber B, Remarque E, Hollingdale MR, Richie TL, Sette A.

Malar J. 2010 Aug 24;9:241. doi: 10.1186/1475-2875-9-241.

41.

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.

Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BK.

Hum Vaccin. 2010 Jan;6(1):97-106. Epub 2010 Jan 21. Review.

PMID:
19946222
42.

Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.

Sedegah M, Rogers WO, Belmonte M, Belmonte A, Banania G, Patterson NB, Rusalov D, Ferrari M, Richie TL, Doolan DL.

Vaccine. 2010 Apr 9;28(17):3055-65. doi: 10.1016/j.vaccine.2009.10.044. Epub 2009 Oct 30.

PMID:
19879998
43.

Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.

Dobaño C, Sedegah M, Rogers WO, Kumar S, Zheng H, Hoffman SL, Doolan DL.

Exp Parasitol. 2009 Jun;122(2):112-23. doi: 10.1016/j.exppara.2009.02.010. Epub 2009 Feb 26.

PMID:
19249301
44.

Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites.

Sedegah M, Weiss WW, Hoffman SL.

Parasite Immunol. 2007 Nov;29(11):559-65.

45.

Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines.

Brice GT, Dobaño C, Sedegah M, Stefaniak M, Graber NL, Campo JJ, Carucci DJ, Doolan DL.

Microbes Infect. 2007 Oct;9(12-13):1439-46. Epub 2007 Aug 3.

PMID:
17913540
46.

A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, Sedegah M, Hayes C, Porter K, Raviprakash K.

J Virol. 2007 Nov;81(21):11634-9. Epub 2007 Aug 22.

47.

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update.

Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, de la Vega P, Sacci J, Richie TL, Hoffman SL.

J Infect Dis. 2007 Jul 1;196(1):145-54. Epub 2007 May 29.

PMID:
17538895
48.

Reduced production of RNA transcripts from individual DNA plasmids given in a multivalent DNA vaccine formula.

Bacon DJ, Sedegah M.

Hum Vaccin. 2007 Mar-Apr;3(2):48-53. Epub 2007 Mar 9.

PMID:
17312401
49.

Immunological responses of neonates and infants to DNA vaccines.

Sedegah M, Hoffman SL.

Methods Mol Med. 2006;127:239-51. Review.

PMID:
16988458
50.

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL.

Vaccine. 2006 Mar 10;24(11):1921-7. Epub 2005 Nov 2.

PMID:
16298024

Supplemental Content

Loading ...
Support Center